BTK and atrial fibrillation: The regimen was generally very well tolerated, with a low number of immune-related adverse events, which have been previously observed with various checkpoint inhibitors40, as well as a low incidence of cardiovascular toxicities, as seen by the lack of atrial fibrillation events, previously associated with first-generation BTK inhibitors41.